Apimeds Pharmaceuticals US (APUS) Debt to Equity (2025)
Apimeds Pharmaceuticals US (APUS) reported Debt to Equity of $0.01 for Q4 2025, up 107.43% quarter-over-quarter from -$0.14 in Q1 2025.
Apimeds Pharmaceuticals US (APUS) Debt to Equity (2025) Analysis & Trends
Apimeds Pharmaceuticals US has reported Debt to Equity for 1 years, with the latest figure at $0.01 in Q4 2025.
- For the quarter ending Q4 2025, Debt to Equity changed N/A year-over-year to $0.01; the trailing twelve-month figure through Dec 2025 stood at $0.01 (changed N/A YoY), and the FY2025 full-year result was $0.01, changed N/A from the prior year.
- Debt to Equity for Q4 2025 stood at $0.01, up from -$0.14 in the prior quarter.
- The five-year high for Debt to Equity was $0.01 in Q4 2025, with the low at -$0.14 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt/Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 2.02 |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 2.80 |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | - |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 0.01 |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | - |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 0.61 |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 0.86 |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | - |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 0.47 |
| 10 | Apimeds Pharmaceuticals US | 13.93 Mn | 10.29 Mn | - | 0.01 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 0.01 |
| Mar 31, 2025 | -0.14 |